Assignee
JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
CN·16 granted patents·14 pending applications·11 citations·filing 2015–2024
Top patents by PatentIndex Score
30 records- 0187US11661437B2Steroid derivative regulators, method for preparing the same, and uses thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted May 30, 2023·3 cites·4 claims
- 0282US12139508B2Steroid derivative regulators, method for preparing the same, and uses thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Nov 12, 2024·2 cites·3 claims
- 0380US11155534B2EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and applicationJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2020·Granted Oct 26, 2021·1 cites·10 claims
- 0479US10759782B2EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and applicationJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2016·Granted Sep 1, 2020·2 cites·4 claims
- 0571US9550747B2Dapagliflozin crystalline form and preparation method thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Jan 24, 2017·3 cites·12 claims
- 0667US2025051387A1Steroid derivative regulators, method for preparing the same, and uses thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2024·Application pending·0 cites
- 0766US2022281847A1Egfr inhibitor free base or acid salt polycrystalline form, preparation method therefor, and applicationJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
- 0864US2022370448A1Pharmaceutical composition comprising third generation small molecule egfr inhibitor and preparation method thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
- 0961US2025170218A1Stable pharmaceutical composition of receptor agonist, and preparation method and application thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2023·Application pending·0 cites
- 1058US2024400582A1Four-membered fused ring compound and preparation method and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
- 1158US2021069190A1Pharmaceutical composition comprising small molecule egfr inhibitor and preparation method thereforJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
- 1254US12377163B2Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Aug 5, 2025·0 cites·40 claims
- 1352US10464915B2Dapagliflozin crystal form and preparation method and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Nov 5, 2019·0 cites·20 claims
- 1447US10836786B2Crystal form of dapagliflozin intermediate and preparation method thereforJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Nov 17, 2020·0 cites·18 claims
- 1546US2023043863A1Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
- 1646US2022168396A1Multi-receptor agonist and medical use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2020·Application pending·0 cites
- 1743US11771773B2Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Oct 3, 2023·0 cites·5 claims
- 1843US11472882B2Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Oct 18, 2022·0 cites·21 claims
- 1942US9840525B2Crystal form of tenofovir prodrug, preparation method thereof, and method of use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Dec 12, 2017·0 cites·20 claims
- 2041US11608332B2FGFR4 inhibitor and preparation method and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Mar 21, 2023·0 cites·4 claims
- 2140US2020247815A1Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2018·Application pending·0 cites
- 2239US11136324B2Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitorsJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2018·Granted Oct 5, 2021·0 cites·18 claims
- 2339US2021355105A1Regulator of nitrogen-containing heteroaromatic derivatives, preparation method therefor and use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
- 2439US2021221822A1Tricyclic derivatives inhibitor, preparation method, and applications thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
- 2537US11667631B2FGFR4 inhibitor, preparation method therefor, and applications thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Jun 6, 2023·0 cites·16 claims
- 2636US10538506B2Crystal form of a potassium-competitive acid blocker and preparation method thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Jan 21, 2020·0 cites·5 claims
- 2735US2018280392A1Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2015·Application pending·0 cites
- 2834US10208065B2Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Feb 19, 2019·0 cites·19 claims
- 2931US2019040025A1Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and applicationJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2017·Application pending·0 cites
- 3028US2018148470A1Cholic acid derivative, and preparation method and medical use thereofJIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →